alirocumab [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory [[serine protease]] synthesized primarily by the [[liver]]. It mainly promotes the degradation of [[low-density lipoprotein receptor]] [[LDL]]-R by binding LDL-R, reducing low-density [[lipoprotein]] [[cholesterol]] (LDL-C) clearance. In addition to regulating LDL-R, PCSK9 inhibitors can also bind [[Toll-like receptor]]s (TLRs), [[SCARB1]] scavenger receptor B (SR-B/CD36), low-density lipoprotein receptor-related protein 1 (LRP1), apolipoprotein E receptor-2 (ApoER2) and very-low-density lipoprotein receptor (VLDL-R) reducing the lipoprotein concentration and slowing [[thrombosis]]. In addition to [[cardiovascular disease]]s, PCSK9 is also used in pancreatic cancer, sepsis, and [[Parkinson's disease]]. Currently marketed PCSK9 inhibitors include [[alirocumab]], [[evolocumab]], and [[inclisiran]], as well as small molecules, [[nucleic acid]] drugs, and [[vaccine]]s under development
((Liu C, Chen J, Chen H, Zhang T, He D, Luo Q, Chi J, Hong Z, Liao Y, Zhang S,
Wu Q, Cen H, Chen G, Li J, Wang L. PCSK9 Inhibition: From Current Advances to
Evolving Future. Cells. 2022 Sep 23;11(19):2972. doi: 10.3390/cells11192972.
PMID: 36230934; PMCID: PMC9562883.)).